U.S. COMPANY FILING
NOVO NORDISK A S — Form 6-K filed 2026-08-04
Filing text preview
Novo Nordisk reported Q2 2026 adjusted sales growth of 7% at CER and adjusted operating profit growth of 11% at CER, and raised its 2026 full-year adjusted sales and operating profit growth outlook to 0% to -6% at CER, from -4% to -12%, driven by increased expectations for GLP-1 product sales.
This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.
Open filing record